Lam Po M, Chung Tony K H, Haines Christopher
Department of Obstetrics and Gynecology, Prince of Wales Hospital, Hong Kong SAR, China.
Gynecol Endocrinol. 2005 Nov;21(5):248-56. doi: 10.1080/09513590500279733.
Recently, two large randomized placebo-controlled studies on long-term postmenopausal hormone replacement therapy, the Heart and Estrogen/progestin Replacement Study (HERS) and the Women's Health Initiative (WHI), have raise a lot of controversies, especially on the cardiovascular aspects. We briefly review these two trials and discuss what we know and do not know about postmenopausal hormone therapy, including the evidence on novel choices such as raloxifene and tibolone.
最近，两项关于绝经后长期激素替代疗法的大型随机安慰剂对照研究，即心脏和雌激素/孕激素替代研究（HERS）以及妇女健康倡议（WHI），引发了诸多争议，尤其是在心血管方面。我们简要回顾这两项试验，并讨论我们对绝经后激素疗法已知和未知的情况，包括关于雷洛昔芬和替勃龙等新选择的证据。
